Palisade Bio Inc. (PALI) Appoints Brian Feagan to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
December 17, 2024 8:30 AM ESTCarlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Â Palisade Bio, Inc. (Nasdaq: PALI) (Palisade, Palisade Bio or the Company), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board.
... More